Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial A. E. Perl,G. Martinelli, J. E. Cortes, A. Neubauer,E. Berman,S. Paolini,P. Montesinos, M. R. Baer,R. A. Larson,C. Ustun,F. Fabbiano,A. Di Stasi,R. Stuart,R. Olin,M. Kasner,F. Ciceri,W. -C. Chou,N. Podoltsev,C. Recher,H. Yokoyama,N. Hosono,S. -S. Yoon,J. -H. Lee,T. Pardee,A. T. Fathi,C. Liu,X. Liu,E. Bahceci,M. J. LevisHAEMATOLOGICA(2019)引用 17|浏览12暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要